[go: up one dir, main page]

NO20004816L - New pharmaceutical formulation - Google Patents

New pharmaceutical formulation

Info

Publication number
NO20004816L
NO20004816L NO20004816A NO20004816A NO20004816L NO 20004816 L NO20004816 L NO 20004816L NO 20004816 A NO20004816 A NO 20004816A NO 20004816 A NO20004816 A NO 20004816A NO 20004816 L NO20004816 L NO 20004816L
Authority
NO
Norway
Prior art keywords
pharmaceutical formulation
new pharmaceutical
preparation
felodipine
dispersed
Prior art date
Application number
NO20004816A
Other languages
Norwegian (no)
Other versions
NO20004816D0 (en
Inventor
Marianne Eklund
Jan-Erik Loefroth
Mats Sundgren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20004816D0 publication Critical patent/NO20004816D0/en
Publication of NO20004816L publication Critical patent/NO20004816L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparat med forlenget fhgivning av felodipin inneholdende den aktive forbindelsen oppløst eller dispergert i et oppløseliggjørende middel samt en fremgangsmåte for fremstilling av preparatet.Preparation with prolonged release of felodipine containing the active compound dissolved or dispersed in a solubilizing agent and a process for the preparation of the preparation.

NO20004816A 1999-07-20 2000-09-26 New pharmaceutical formulation NO20004816L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902742A SE9902742D0 (en) 1999-07-20 1999-07-20 New pharmaceutical formultion
PCT/SE1999/002474 WO2001005376A1 (en) 1999-07-20 1999-12-22 New pharmaceutical formulation

Publications (2)

Publication Number Publication Date
NO20004816D0 NO20004816D0 (en) 2000-09-26
NO20004816L true NO20004816L (en) 2000-11-02

Family

ID=20416534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004816A NO20004816L (en) 1999-07-20 2000-09-26 New pharmaceutical formulation

Country Status (9)

Country Link
EP (1) EP1113786A1 (en)
JP (1) JP2003504392A (en)
KR (1) KR20010078703A (en)
CN (1) CN1319004A (en)
AU (1) AU3095600A (en)
CA (1) CA2328102A1 (en)
NO (1) NO20004816L (en)
SE (1) SE9902742D0 (en)
WO (1) WO2001005376A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211149A1 (en) * 2002-05-07 2003-11-13 Sherman Bernard Charles Extended release tablets comprising felodipine
GB0222612D0 (en) * 2002-09-30 2002-11-06 Univ Gent Controlled delivery system for bioactive substances
EA011614B1 (en) * 2004-11-17 2009-04-28 Арес Трейдинг С.А. Benzothiazole formulations and use thereof
CN101103964B (en) * 2006-07-14 2010-09-29 海南盛科生命科学研究院 A kind of sustained-release preparation containing felodipine and preparation method thereof
KR100841877B1 (en) * 2006-08-31 2008-06-27 조선대학교산학협력단 Controlled-release formulations of topically solubilized poorly soluble drugs and methods for preparing the same
CN102784128B (en) * 2012-07-31 2015-01-07 北京协和药厂 Felodipine sustained release preparation and preparation method of felodipine sustained release preparation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601624D0 (en) * 1986-04-11 1986-04-11 Haessle Ab NEW PHARMACEUTICAL PREPARATIONS
DE3738236A1 (en) * 1987-11-11 1989-05-24 Euro Celtique Sa BIT CAPSULE
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
WO1999021534A1 (en) * 1997-10-27 1999-05-06 Merck Patent Gmbh Solid state solutions and dispersions of poorly water soluble drugs

Also Published As

Publication number Publication date
CA2328102A1 (en) 2001-01-20
WO2001005376A1 (en) 2001-01-25
KR20010078703A (en) 2001-08-21
EP1113786A1 (en) 2001-07-11
NO20004816D0 (en) 2000-09-26
SE9902742D0 (en) 1999-07-20
CN1319004A (en) 2001-10-24
AU3095600A (en) 2001-02-05
JP2003504392A (en) 2003-02-04

Similar Documents

Publication Publication Date Title
NO2025027I1 (en) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - extended.
FI971776A0 (en) Compounds and compositions for the administration of active substances
SV2004001556A (en) ACID PREPARATIONS OF INSULIN WITH IMPROVED STABILITY
NO20004353L (en) New pyridazine derivatives and drugs containing these as active ingredients
HUP0203451A2 (en) Pharmaceutical compositions of anti-tubercular drugs and process for their preparation
EE200100505A (en) Use of Modified Starch in Hydrophilic Controlled Release Preparation, Hydrophilic Controlled Release Preparation, Method of Preparation and Use, and Dosage Form
ATE329897T1 (en) COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE SUBSTANCES
BRPI0015567B8 (en) compound, pharmaceutical composition, dosage unit form, use of the pharmaceutical composition and method for preparing a pharmaceutical composition
EE05620B1 (en) Omeprazole microgranules, process for their preparation and pharmaceutical preparations
DE60105448D1 (en) SOLID DISPERSIONS WITH NITRATIVE ACTIVE INGREDIENTS
PL366855A1 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
SE0102843D0 (en) Stabilized oral pharmaceutical composition containing lodide and lodate and method
EE04997B1 (en) Pharmaceutical composition containing loteprednol and antihistamines, a medicament containing these agents, a process for the preparation of the medicament and use of a combination of these agents
EE05054B1 (en) Oral pharmaceutical composition of a 5-HT4 agonist or antagonist and its use in medicine
NO20004816L (en) New pharmaceutical formulation
BR0206960A (en) Oral pharmaceutical composition and use of a hydroxypropyl methylcellulose phthalate polymer
DE69933671D1 (en) ADENOSINE A1 ANTAGONISTS AGAINST MALE STERILITY
SE0001916D0 (en) Novel formulation
AR014082A1 (en) ORAL SERTRALINE CONCENTRATE
GEP20043377B (en) Pharmaceutical Complex
NO950950L (en) Pharmaceutical preparation
DK1071397T3 (en) Levosimendan-containing drugs for oral administration with controlled release of the active agent
SE9604752D0 (en) Formulation and use
DE59205998D1 (en) Medicament with antineoplastic activity containing octadecyl- [2- (N-methylpiperidino) ethyl] phosphate as active ingredient and process for its preparation
ITMI20020872A1 (en) HYPERPHORINE DERIVATIVES THEIR USE AND FORMULATIONS CONTAINING THEM

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application